DEVELOPMENT OF MESALAZINE MICROSPHERES FOR COLON TARGETING

KATTA RAJESH, R. DEVESWARAN*, S. BHARATH, B. V. BASAVARAJ

Department of Pharmaceutics, Faculty of Pharmacy, M. S. Ramaiah University of Applied Sciences, Bangalore 560054
Email: deveswaran.ps.ph@msruas.ac.in

Received: 28 Jan 2017, Revised and Accepted: 14 Jun 2017

ABSTRACT

Objective: The present work was aimed at preparation of mesalazine microspheres by a non-aqueous solvent evaporation method using eudragit S 100 and eudragit L 100 as pH dependent polymers for colon targeting.

Methods: The ratio of drug to polymer was varied and the effect of formulation variables revolutions per minute (RPM) (1000, 1500, 2000 and 2500) and concentration of span 80 (1%, 1.5%, 2% and 2.5%) were studied. Prepared microspheres were evaluated for particle size, percent drug entrapment, granular analysis, in vitro drug release studies, Fourier transformed infrared spectroscopy (FT-IR) Differential Scanning Calorimetry (DSC), X-ray diffraction (XRD) and scanning electron microscopy (SEM) studies.

Results: Particle size has decreased and percent drug entrapment had increased with increase in RPM in all formulations. When the span 80 concentration increased, the particle size of the microsphere formulations increased and percent drug entrapment decreased in eudragit S 100 microspheres; whereas in eudragit L 100 microspheres, as the concentration of span 80 increased, the particle size of the microsphere formulations decreased. The prepared microspheres sustained the drug release over a period of 12 h.

Conclusion: Thus eudragit S 100 and eudragit L 100 microspheres could constitute a promising approach for colon-specific and sustained delivery of mesalazine for the treatment of inflammatory bowel disease.

Keywords: Microspheres, Mesalazine, Eudragit S 100, Solvent evaporation, Inflammatory bowel disease

INTRODUCTION

Oral drug delivery system is one of the frontier areas of delivering a drug with the cost-effectiveness of dosage form and treatment, patient compliance, optimum drug delivery and bioavailability [1]. There has been a remarkable improvement in the field of novel drug delivery systems. Carrier technology is an approach for drug delivery by the union of the drug to a carrier particle such as microspheres, nanoparticles, liposomes, etc. which modulates the release and absorption characteristics of the drug [2].

Colon-specific drug delivery systems have gained increasing attention for the treatment of diseases such as Crohn’s disease, ulcerative colitis and irritable bowel syndrome [3]. Single unit dosage forms such as tablets and capsules for modified release colonic delivery suffer from problems such as unpredictable gastric emptying, gastrointestinal (GI) transit variations resulting from inter-subject variability in transit patterns and incomplete drug delivery in GI tract due to the risk of not dissolving the polymer coat on the large, low surface area coated tablets. On the other hand, multi-particulate drug delivery system for colonic delivery shows several advantages over single-unit dosage forms. Being of smaller size, it is expected to provide less inter and intra-individual variability, more rapid and uniform gastric emptying, more uniform dispersion and reproducible transit through GI tract [4, 5]. However, in microparticulate delivery systems, it is challenging to develop a colon-targeted sustained-release dosage form. Microspheres are homogeneous, monolithic particles which improve the treatment by providing localization of the drug at the site of action and by prolonging the drug release [6]. It suffers from the risk of early dissolution and release of the drug before reaching the colon due to its large surface area [7, 8].

Mesalazine (5-aminosalicylic acid, 5-ASA) is widely used in long-term treatment of ulcerative colitis by its topical mode of action on the inflammation in colonic mucosa. In order to achieve effective oral mesalazine treatment with minimal side effect and acceptable patient compliance, the delivery system has to overcome many obstacles. The effective use of the currently marketed mesalazine formulations requires multiple daily dosing with up to 12 tablets or capsules [9, 10].

Upon oral administration, mesalazine exhibits rapid and nearly complete absorption from the upper intestine, resulting not only in systemic side effects but also in lowering the dose reaching the colon with the subsequently decreased probability of therapeutic success [11]. In ulcerative colitis, inflammation is observed in all regions of the colon. Accordingly, in order to overcome these problems, in formulating mesalazine in a successful delivery system, it is important to minimise 5-ASA release in the upper gastrointestinal tract and to localize mesalazine release in the colon in a sustained release manner. If mesalazine is released in a pulsatile manner in the ascending colon, it would be diluted during its passage in the colon, consequently, a scarce concentration of mesalazine could be delivered to the transverse and descending colon resulting in reduced clinical effectiveness.

This is more difficult in the case of mesalazine due to its physicochemical properties. mesalazine exhibits amphoteric property, its solubility is increased at acidic pH values (pH<2) in the stomach and at more alkaline values (pH>5.5) in the lower part of the small intestine. This necessitates the development of pH-dependent, colon-targeted, sustained release mesalazine microspheres. The goal of this work was to prepare mesalazine microspheres by a non-aqueous solvent evaporation method employing pH-dependent polymers like eudragitS100 and eudragit L 100.

MATERIALS AND METHODS

Materials
Mesalazine was purchased from BEC Chemicals, Mumbai. Eudragit S 100 and Eudragit L 100 were procured from Yarrow Chem Products, Mumbai. Magnesium stearate was purchased from Central Drug House Pvt. Limited, New Delhi. Acetone and liquid paraffin heavy was purchased from Rankem, New Delhi. Span 80 was purchased from NR CHEM, Mumbai. All other reagents used were of analytical grade.

Preparation methods
Microspheres containing mesalazine were prepared by a non-aqueous solvent evaporation technique. Mesalazine and the
specified amount of magnesium stearate were dispersed in acetone to which eudragit S 100 was previously dissolved. The resulting suspension was added at once to a specified amount of liquid paraffin containing 2% (v/v) span 80 and stirred at 1500 revolutions per minute (RPM) for 3 h using a mechanical stirrer under ambient conditions (table 1). Stirring was continued until the organic solvent evaporated completely. The microspheres were filtered, washed with n-hexane, dried overnight and then stored in desiccators until further use [12]. The same procedure was repeated using eudragit L 100.

Table 1: Batch specifications of preliminary formulations

<table>
<thead>
<tr>
<th>S. No.</th>
<th>Formulation code</th>
<th>Drug: polymer ratio</th>
<th>Stirring speed (RPM)</th>
<th>Emulsifier Concentration (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>F1</td>
<td>1:1</td>
<td>1500</td>
<td>2</td>
</tr>
<tr>
<td>2</td>
<td>F2</td>
<td>1:2</td>
<td>1500</td>
<td>2</td>
</tr>
<tr>
<td>3</td>
<td>F3</td>
<td>1:3</td>
<td>1500</td>
<td>2</td>
</tr>
<tr>
<td>4</td>
<td>F4</td>
<td>1:4</td>
<td>1500</td>
<td>2</td>
</tr>
<tr>
<td>5</td>
<td>F5</td>
<td>1:5</td>
<td>1500</td>
<td>2</td>
</tr>
<tr>
<td>6</td>
<td>F6</td>
<td>1:1</td>
<td>1500</td>
<td>2</td>
</tr>
<tr>
<td>7</td>
<td>F7</td>
<td>1:2</td>
<td>1500</td>
<td>2</td>
</tr>
<tr>
<td>8</td>
<td>F8</td>
<td>1:3</td>
<td>1500</td>
<td>2</td>
</tr>
<tr>
<td>9</td>
<td>F9</td>
<td>1:4</td>
<td>1500</td>
<td>2</td>
</tr>
<tr>
<td>10</td>
<td>F10</td>
<td>1:5</td>
<td>1500</td>
<td>2</td>
</tr>
</tbody>
</table>

FT-IR studies

The drug and polymer interactions were studied by Fourier transform infrared spectroscopy by KBr disc method. The spectra were recorded for the pure drug, polymer and the physical mixture of drug and polymer in the ratio 1:1 at the scanning range of 400-4000 cm⁻¹ using FTIR-8400S, spectrophotometer (SHIMADZU, Japan).

DSC studies

The DSC analysis of pure drug, polymer and the physical mixture of drug and polymer were carried out using differential scanning calorimeter (PERKIN ELMER-Pyris 1). Samples of about 5 mg was placed in a 50μl perforated aluminium pan and sealed. Heat runs for each sample were set from 5 °C to 300 °C using nitrogen as purging gas and samples were analyzed.

XRD studies

Powder XRD of mesalazine, eudragit S-100, eudragit L-100, formulation mixture of mesalazine with eudragit S-100, Formulation mixture of mesalazine with eudragit L-100 was recorded using Bruker AXS D8 Advance diffractometer with Si(Li) PSD detector. The operation data were: measuring circle diameter-435, 500 and 600 mm predetermined; angle range-360°; X-ray source-Cu, wavelength 1.5406Å.

Characterization of prepared microspheres

Micromeritic studies

The microspheres were characterized for their micromeritic properties such as tap density, bulk density, Carr’s index, Hausner’s ratio and angle of repose. All the analysis was carried out in triplicate [13].

Yield of microspheres

The percentage yield of microspheres was calculated by the following formula,

\[
\text{% yield} = \frac{\text{Actual weight of product}}{\text{Total weight of drug and excipient}} \times 100
\]

Scanning electron microscopy

The surface morphology of prepared microspheres was observed under scanning electron microscope (JEOL, JSM-T, Japan). Dry microspheres were placed on an electron microscope brass stub and coated with gold to a thickness of about 200 Å using a sputter coater in an ion sputter. Pictures of the microspheres were taken by randomly scanning the stub with the help of SEM analyzer.

Particle size determination

The microspheres were observed under 100X magnification in an optical microscope (Olympus LITE image) and an average of 100 particles was counted.

Drug entrapment efficiency

Accurately weighed the quantity of microspheres equivalent to 100 mg of mesalazine was taken in 100 ml volumetric flask and dissolved in 50 ml of 25% sodium acetate solution using sonication for 15 min and the volume was made up to 100 ml with 25% sodium acetate solution. The resulting solution was diluted suitably with water and filtered through Whatman filter paper No: 41. The absorbance of the resulting solution was measured at 240 nm, using distilled water as a blank. All the analysis was carried out in triplicate. The percentage drug entrapment was determined using the following equation,

\[
\text{% drug entrapment efficiency} = \frac{\text{Amount of drug actually present}}{\text{Theoretical drug loaded expected}} \times 100
\]

In vitro drug release studies

In vitro drug release was studied using dissolution test apparatus USP type I method (rotating basket method). The drug loaded microspheres equivalent to 100 mg of mesalazine were introduced into 900 ml of dissolution medium which was maintained at 37±0.5°C and stirred at 100 rpm. The dissolution was carried out in 0.1N hydrochloric acid for first 2 h followed by 4.5pH acetate buffer for next 2 h and 7.4 pH buffers containing rat fecal content for next 8 h to mimic the GIT transit to colon region [14]. 5 ml of the aliquot was withdrawn at regular predetermined intervals and sink conditions were maintained throughout the study by replacing an equal volume of fresh dissolution medium. The samples were diluted suitably with distilled water and analysed spectro-photometrically at 240 nm. All the analysis was carried out in triplicate.

Drug release kinetics

Data obtained from in vitro drug release studies were fitted to various kinetic models like zero-order, 1st order, Higuchi, Korsemeyer and Peppas using PCP Disso V2 software to predict the drug release mechanism.

Stability studies

Based on the International Conference on Harmonization (ICH) guidelines [15, 16] the stability studies were carried out in an environmental chamber (Tempo Instruments, India). Microsphere formulations F13 and F20 were stored at 40 °C±2 °C and 75±5% RH for a period of 6 mo. At intervals of 0, 2, 4 and 6 mo for accelerated storage condition, the samples were tested for changes in physical appearance and drug content.

RESULTS AND DISCUSSION

FTIR studies

Eudragit S 100 (in fig. 1a)showed hydroxyl group stretching (-OH) at 2989 cm⁻¹, alkyl group (CH-R) stretching at 2997 cm⁻¹, the ester
linkage (C=O-O-R) stretching at 1726 cm\(^{-1}\), carboxylic acid (C=O-OH) stretching was observed at 1708 cm\(^{-1}\), alkyl group (CH-R) bending at 1386, 1448, 1483 cm\(^{-1}\) and carboxylic acid bending peaks at 1159, 1188, 1263 cm\(^{-1}\). Fig. 1b represents the FT-IR spectra of eudragit L 100. The characteristic peaks of eudragit L 100 are hydroxyl group (OH) stretching at 3494 cm\(^{-1}\), alkyl group (CH-R) stretching at 2993 cm\(^{-1}\), the ester linkage (C=O-O-R) stretching at 1784 cm\(^{-1}\), carboxylic acid (C=O-OH) stretching at 1724 cm\(^{-1}\), alkyl group (CH-R) bending at 1384, 1448, 1487 cm\(^{-1}\) and carboxylic acid bending peaks at 1161, 1186, 1261 cm\(^{-1}\). Magnesium stearate showed absorptions peaks at 2914 and 2486 cm\(^{-1}\) due to C-H stretching of the molecule. The other bands located at 1581, 1476 cm\(^{-1}\) are due to the COO-group stretching (in fig. 1c).

The characteristic peaks of mesalazine are carboxylic acid stretch R-C=O-OH with peaks at 3342 and 1315 cm\(^{-1}\), C=O stretch at 1789 cm\(^{-1}\),-C\(_6\)H\(_5\) aromatic ring stretch at 1645 cm\(^{-1}\),-C-H (aromatic) stretch at 1452 cm\(^{-1}\) and-C=C (aromatic) at 1490 cm\(^{-1}\). The bending peaks of meta, para-substituted benzene was observed at 811 cm\(^{-1}\) and the -R-NH\(_2\) bending peak was observed at 686 cm\(^{-1}\) (fig. 1d). FT-IR spectra of physical mixture of mesalazine with eudragit S 100 and eudragit L 100 showed characteristic peaks of carboxylic acid stretch R-C=O-OH, observed at 3409 and 1315 cm\(^{-1}\), C=O stretch at 1789 cm\(^{-1}\),-C\(_6\)H\(_5\) aromatic ring stretch at 1645 cm\(^{-1}\),-C-H (aromatic) stretch at 1452 cm\(^{-1}\) and-C=C (aromatic) stretch at 1490 cm\(^{-1}\). The above results confirmed the absence of drug interaction within the polymers (fig. 1e and 1f).

![FT-IR Graphs of a) eudragit S 100; b) eudragit L 100; c) Mg stearate; d) mesalazine; e) mesalazine+eudragit S 100; f) mesalazine+eudragit L 100](image)

**DSC studies**

DSC thermogram of pure drug mesalazine (fig. 2a) showed a characteristic exothermic peak at 294.52 °C, which was within the range of melting point of mesalazine. Eudragit L-100 and eudragit S-100 exhibited a similar exothermic peak at 239.84 °C and 222.86 °C respectively (fig. 2b and 2c). The observed melting point range was found to be in close proximity to the
values reported. Mesalazine peak was found at 287.11°C in a physical mixture of mesalazine with eudragit S-100 (fig. 2d) and in a physical mixture of mesalazine with eudragit L-100, a characteristic peak was observed at 289.11°C (fig. 2e). This study confirmed that there was no interaction between the drug and polymers used.

![DSC Curves](image)

**Fig. 2: DSC Curves of a) mesalazine; b) eudragit L 100; c) eudragit S 100; d) mesalazine+eudragit S 100; e) mesalazine+eudragit L 100**

**XRD studies**

The powder XRD curves were represented in the fig. 3. The 2θ values from the powder XRD studies for mesalazine was found to be 14.956° (fig. 3a) and a sharp intense peak indicated the crystallinity of the drug. The 2θ value of eudragit L-100 was found to be 42.709° (fig. 3b) indicating its crystalline nature. The 2θ value of eudragit S-100 was found to be 14.487° (fig. 3c) and confirmed its amorphous nature by a broad peak. A physical mixture of mesalazine with Eudragit S-100 showed a sharp intense peak at 15.167° (represented in the fig. 3d) and that of mesalazine with eudragit L-100 showed a sharp peak at 15.084° (represented in the fig. 3e) indicating that the drug and the polymer existed in the crystalline state.
The percentage yield ranged from 87.96% to 99.78% for eudragit S 100 microspheres and 86.79% to 95.86% for eudragit L 100 microspheres. Particle size was found to be in the range of 265.26±1.9μm to 301.21±0.2μm with eudragit S 100 microspheres and 295.09±2.8μm to 367.93±2.3μm with eudragit L 100 microspheres. The percent drug entrapment was found to be in the range of 85.56% to 99.12% for all formulations of eudragit S 100 microspheres and 79.52% to 96.54% for formulations made with eudragit L 100. The granular analysis of the prepared microspheres was performed and flow property was found to be best for formulation F5 (22° 43) using eudragit S 100 and for formulation F8 (24° 93) using eudragit L 100. Bulk density was found to be least for formulation F10 at 0.3526g/cc and maximum for formulation F6 at 0.4968g/cc. Tap density was found to be in the range of 0.4850g/cc to 0.7443g/cc for all the prepared microsphere formulations. The bulkiness was observed to be in the range of 2.0128 to 2.8360. The Carr’s index was found to be in the range of 20% to 46.1% and Hausner’s ratio was found to be in the range of 1.25 to 1.85 for all the microsphere formulations. The results were shown in table 2.
Table 2: Characterization of prepared microspheres

<table>
<thead>
<tr>
<th>Formulation code</th>
<th>Percentage yield*</th>
<th>Particle size (μm)*</th>
<th>Drug entrapment (%)*</th>
<th>Bulk density (g/cc)</th>
<th>Tap density (g/cc)*</th>
<th>Hausner’s ratio*</th>
<th>Angle of repose (θ)</th>
<th>Carr’s index (%)*</th>
<th>Bulkiness (ml/g)*</th>
</tr>
</thead>
<tbody>
<tr>
<td>F1</td>
<td>95.7±0.90</td>
<td>275.35±1.6</td>
<td>85.5±0.36</td>
<td>0.385±0.04</td>
<td>0.61±0.04</td>
<td>1.61±0.5</td>
<td>25°±0.5</td>
<td>37.5±0.3</td>
<td>2.59±0.61</td>
</tr>
<tr>
<td>F2</td>
<td>87.9±0.65</td>
<td>290.8±6.32</td>
<td>90.1±0.45</td>
<td>0.36±0.03</td>
<td>0.485±0.06</td>
<td>1.3±0.6</td>
<td>26°±15</td>
<td>25.1±0.4</td>
<td>2.74±0.54</td>
</tr>
<tr>
<td>F3</td>
<td>89.9±0.74</td>
<td>301.2±1.02</td>
<td>92.5±0.98</td>
<td>0.42±0.02</td>
<td>0.58±0.03</td>
<td>1.37±0.4</td>
<td>28°±49</td>
<td>27.2±0.2</td>
<td>2.33±0.32</td>
</tr>
<tr>
<td>F4</td>
<td>91.5±0.63</td>
<td>290.8±5.2</td>
<td>95.3±0.35</td>
<td>0.46±0.04</td>
<td>0.775±0.04</td>
<td>1.25±0.3</td>
<td>25°±96</td>
<td>20.3±0.3</td>
<td>2.17±0.45</td>
</tr>
<tr>
<td>F5</td>
<td>99.9±0.84</td>
<td>305.2±6.1</td>
<td>99.1±0.47</td>
<td>0.45±0.03</td>
<td>0.58±0.05</td>
<td>1.27±0.5</td>
<td>22°±43</td>
<td>21.4±0.4</td>
<td>2.19±0.24</td>
</tr>
<tr>
<td>F6</td>
<td>86.7±0.37</td>
<td>295.0±9.28</td>
<td>79.5±0.55</td>
<td>0.49±0.05</td>
<td>0.74±0.03</td>
<td>1.49±0.6</td>
<td>26°±45</td>
<td>33.2±0.6</td>
<td>2.01±0.3</td>
</tr>
<tr>
<td>F7</td>
<td>88.9±0.91</td>
<td>367.9±3.2</td>
<td>84.6±0.87</td>
<td>0.38±0.03</td>
<td>0.678±0.04</td>
<td>1.74±0.5</td>
<td>27°±58</td>
<td>42.58±0.3</td>
<td>2.56±0.80</td>
</tr>
<tr>
<td>F8</td>
<td>95.8±0.57</td>
<td>280.4±7.0</td>
<td>96.5±0.49</td>
<td>0.40±0.02</td>
<td>0.676±0.04</td>
<td>1.66±0.4</td>
<td>24°±93</td>
<td>39.99±0.2</td>
<td>2.46±0.30</td>
</tr>
<tr>
<td>F9</td>
<td>93.7±0.69</td>
<td>336.2±12.8</td>
<td>95.6±0.34</td>
<td>0.40±0.05</td>
<td>0.685±0.03</td>
<td>1.70±0.4</td>
<td>30°±57</td>
<td>41.38±0.4</td>
<td>2.49±0.20</td>
</tr>
<tr>
<td>F10</td>
<td>89.9±0.78</td>
<td>295.1±1.4</td>
<td>91.5±0.26</td>
<td>0.352±0.03</td>
<td>0.65±0.02</td>
<td>1.85±0.2</td>
<td>25°±46</td>
<td>46.10±0.2</td>
<td>2.83±0.60</td>
</tr>
</tbody>
</table>

*(n=3) (average±SD)

SEM studies

Scanning electron microscopy of the formulations revealed that the surface morphology of the prepared microspheres was found to be spherical. The surface of the spheres was rough with abrasions on it (fig. 4a and 4b).

In vitro drug release studies

The percentage drug release was found best in formulation F5 with 101.45% release and least drug release was observed in formulation F2 with 94.39% at the end of 11th h for microspheres prepared with eudragit S 100. The drug release was found best in formulation F8 with 99.69% and least drug release was observed with 96.66% in formulation F10 to the end of 11 h f or microspheres prepared with eudragit L 100. The plot for cumulative drug release profiles for all the mesalazine formulations prepared using eudragit S 100 and L 100 was shown in the fig. 5 and 6. The drug release for the formulations was found to be less than 30% till the end of 4th hour after which there is a rapid release of drug by the end of 11 h. Even if the microspheres did not burst, large swelling occurred and thus increased matrix porosity. These findings comply well with the higher drug to polymer ratio used in formulations [17]. This release shows the pH sensitivity of the polymer which releases the drug only in the colon region.

![Fig. 4a: Microspheres of eudragit S-100](image)

![Fig. 4b: Microspheres of eudragit L-100](image)

![Fig. 5: Drug release profile of formulations with eudrait S-100 (n=3)](image)
Drug release kinetics

The best fit model was found to be Peppas for formulations F1, F2, F5, F7, F8, F9, and F10, whereas formulations F3, F4, and F6 showed zero order release kinetics.

Effect of process variables on formulations

Among the mesalazine microspheres prepared using Eudragit S 100, formulation F5 was selected as the best and from the formulations prepared using Eudragit L 100, formulation F8 was selected as the best based on their in vitro drug release profile. The effects of process variables on these 2 formulations F5 and F8 were studied.

Effect of concentration of span 80 on mesalazine loaded eudragit S 100 microspheres

Three formulations F11, F12 and F13 were prepared using mesalazine and eudragit S 100 in the ratio of 1:5 and varying span 80 concentration by 1%, 1.5% and 2.5% but fixed RPM at 1500. As the concentration of span 80 increased, the particle size of the microsphere formulations increased, whereas the percent drug entrapment decreased. This could be due to the increase in the viscosity of the medium.

Effect of RPM on mesalazine loaded eudragit S 100 microspheres

Three formulations F14, F15 and F16 were prepared using mesalazine and eudragit S 100 in the ratio of 1:5 with fixed span concentration of 2% but, by varying RPM viz. 1000, 2000 and 2500. As the RPM increased, the particle size of the microsphere formulations decreased and the percent drug entrapment increased. This could be due to the increase in the viscosity of the medium.

<table>
<thead>
<tr>
<th>S. No.</th>
<th>Formulation code</th>
<th>Drug: polymer ratio</th>
<th>Stirring speed</th>
<th>Emulsifier concentration (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>F11</td>
<td>1:5</td>
<td>1500</td>
<td>1</td>
</tr>
<tr>
<td>2</td>
<td>F12</td>
<td>1:5</td>
<td>1500</td>
<td>1.5</td>
</tr>
<tr>
<td>3</td>
<td>F13</td>
<td>1:5</td>
<td>1500</td>
<td>2</td>
</tr>
<tr>
<td>4</td>
<td>F14</td>
<td>1:5</td>
<td>1000</td>
<td>2</td>
</tr>
<tr>
<td>5</td>
<td>F15</td>
<td>1:5</td>
<td>2000</td>
<td>2</td>
</tr>
<tr>
<td>6</td>
<td>F16</td>
<td>1:5</td>
<td>2500</td>
<td>2</td>
</tr>
</tbody>
</table>

Effect of RPM on mesalazine loaded eudragit L 100 microspheres

Three formulations F17, F18 and F19 were prepared with mesalazine and eudragit L 100 in the ratio of 1:3 with fixed span concentration of 2% but, by varying RPM viz. 1000, 2000 and 2500 respectively. As the RPM increased, the particle size of the microsphere formulations decreased, whereas the percent drug entrapment increased. This could be due to the increase in the viscosity of the medium.

Effect of concentration of Span 80 on mesalazine loaded eudragit L 100 microspheres

Three formulations F20, F21 and F22 were prepared using mesalazine and eudragit L 100 in the ratio of 1:3 and with a fixed RPM of 1500 but, by varying span concentration viz. 1%, 1.5% and 2.5% respectively. As the concentration of span 80 increased, the particle size of the microsphere formulations decreased, but after a certain extent, the particle size increased. A similar effect was found in case of percent drug entrapment which decreased initially and later increased. This is due to better stabilisation of internal droplets.
Characterization of mesalazine microspheres for optimized formulations

The optimised microsphere formulations were characterized for parameters such as percentage yield, particle size, percent drug entrapment, granular analysis and the results were shown in table 5. The percentage yield of microspheres ranged from 87.36% to 98.78% for formulations prepared with eudragit S 100 and 85.42% to 98.59% for formulations prepared with eudragit L 100. The particle size was found to be ranging from 227.12±1.4μm to 378.89±2.5μm for eudragit S 100 microspheres and 230.54±3.4μm to the 345.57±2.4μm range for eudragit L 100 microspheres. The percent drug entrapment was found to be in the range of 98.78% to 98.54% for eudragit S 100 microspheres and 84.32% to 98.97% for eudragit L 100 microspheres.

The drug release for the formulations was found to be the formulations prepared using eudragit S 100 and L 100 were shown with 73.25% in formulation F22 to the end of 12 h using eudragit L formulation F20 with 93.42% and least drug release was observed eudragit S 100 as a polymer. The drug release was found best in the formulations F13 for eudragit S 100 and F20 for eudragit L 100.

In vitro drug release studies

The percentage drug release was found to be best in microsphere formulation F13 with 100.51% release and least drug release was observed in formulation F16 with 89.72% at the end of 12th hour using eudragit S 100 as a polymer. The drug release was found best in formulation F20 with 93.42% and least drug release was observed with 73.25% in formulation F22 to the end of 12 h using eudragit L 100 as a polymer. The plot for cumulative drug release profiles for all the formulations prepared using eudragit S 100 and L 100 were shown in the fig. 7, 8. The drug release for the formulations was found to be less than 25% till the end of 4th hour after which there is a rapid release of drug by the end of 12 h. This release shows the pH sensitivity of the polymer which releases the drug only in the colon region.

Drug release kinetics

The best fit model was found to be Peppas for formulations F11, F12, F13, F14, F15, F16, F17, F18, F19, F20 and F22, whereas formulations F21 showed zero order release kinetics.

Stability studies

Table 6 represents the results of stability studies for the prepared microsphere formulations. The drug entrapment efficiency and the physical appearance of the microspheres were examined for formulations F13 for eudragit S 100 and F20 for eudragit L100 at various time intervals of 2, 4 and 6 mo by storing them in accelerated conditions (40 °C±2 °C/75% RH±5%). The results of percentage drug entrapment efficiency and physical appearance of both the formulations were close to that of initial data with very slight variations suggesting that it has an acceptable stability on storage. The similarity factor (f2) for a modified release dosage form was used as a basis to compare the dissolution profiles of the best formulations at 2, 4 and 6 mo with the initial day. The similarity factor values for 2, 4 and 6 mo were found to be 67.89, 64.25 and 60.32 respectively indicating the closest fit to the initial day dissolution profile.

Table 5: Characterization of optimised mesalazine microsphere formulations

<table>
<thead>
<tr>
<th>Formulation code</th>
<th>% yield*</th>
<th>Particle size* (μm)</th>
<th>Drug entrapment (%)</th>
<th>Bulk density (g/cc)</th>
<th>Tap density (g/cc)</th>
<th>Bulkiness (ml/g)*</th>
<th>Carr’s index (%)*</th>
<th>Hauser’s ratio*</th>
<th>Angle of repose (°)</th>
</tr>
</thead>
<tbody>
<tr>
<td>F11</td>
<td>98.78±0.65</td>
<td>25.92±1.4</td>
<td>98.54±0.35</td>
<td>0.384±0.04</td>
<td>0.598±0.03</td>
<td>2.60±0.42</td>
<td>35.76±0.3</td>
<td>1.55±0.4</td>
<td>29° 76’</td>
</tr>
<tr>
<td>F12</td>
<td>91.35±0.34</td>
<td>287.78±3.2</td>
<td>92.54±0.24</td>
<td>0.280±0.04</td>
<td>0.392±0.06</td>
<td>3.57±0.31</td>
<td>22.57±0.4</td>
<td>1.40±0.3</td>
<td>24° 25’</td>
</tr>
<tr>
<td>F13</td>
<td>95.56±0.21</td>
<td>346.67±1.8</td>
<td>94.88±0.39</td>
<td>0.314±0.06</td>
<td>0.48±0.04</td>
<td>3.18±0.28</td>
<td>29.98±0.3</td>
<td>1.42±0.2</td>
<td>25° 26’</td>
</tr>
<tr>
<td>F14</td>
<td>87.36±0.07</td>
<td>378.09±2.5</td>
<td>89.78±0.21</td>
<td>0.318±0.03</td>
<td>0.557±0.05</td>
<td>3.13±0.36</td>
<td>42.86±0.2</td>
<td>1.75±0.4</td>
<td>30° 18’</td>
</tr>
<tr>
<td>F15</td>
<td>90.34±0.39</td>
<td>281.36±0.9</td>
<td>91.35±0.19</td>
<td>0.285±0.04</td>
<td>0.392±0.02</td>
<td>3.50±0.34</td>
<td>27.28±0.6</td>
<td>1.37±0.5</td>
<td>24° 08’</td>
</tr>
<tr>
<td>F16</td>
<td>94.90±0.22</td>
<td>237.12±1.4</td>
<td>97.89±0.41</td>
<td>0.420±0.03</td>
<td>0.630±0.04</td>
<td>2.38±0.43</td>
<td>33.37±0.7</td>
<td>1.54±0.6</td>
<td>23° 45’</td>
</tr>
<tr>
<td>F17</td>
<td>85.42±0.41</td>
<td>345.57±2.4</td>
<td>94.32±0.53</td>
<td>0.359±0.05</td>
<td>0.567±0.04</td>
<td>2.78±0.17</td>
<td>36.7±0.5</td>
<td>1.58±0.4</td>
<td>26° 78’</td>
</tr>
<tr>
<td>F18</td>
<td>92.56±0.30</td>
<td>276.62±2.8</td>
<td>94.58±0.44</td>
<td>0.381±0.06</td>
<td>0.579±0.05</td>
<td>2.62±0.26</td>
<td>34.12±0.6</td>
<td>1.51±0.5</td>
<td>26° 91’</td>
</tr>
<tr>
<td>F19</td>
<td>89.56±0.39</td>
<td>230.54±3.4</td>
<td>91.65±0.37</td>
<td>0.360±0.04</td>
<td>0.478±0.06</td>
<td>2.77±0.19</td>
<td>24.62±0.5</td>
<td>1.32±0.3</td>
<td>28° 54’</td>
</tr>
<tr>
<td>F20</td>
<td>96.52±0.56</td>
<td>298.05±1.6</td>
<td>97.93±0.24</td>
<td>0.546±0.03</td>
<td>0.681±0.04</td>
<td>1.83±0.21</td>
<td>24.78±0.4</td>
<td>1.24±0.3</td>
<td>23° 29’</td>
</tr>
<tr>
<td>F21</td>
<td>93.56±0.73</td>
<td>256.48±2.2</td>
<td>94.35±0.69</td>
<td>0.293±0.02</td>
<td>0.470±0.06</td>
<td>3.40±0.31</td>
<td>37.51±0.6</td>
<td>1.60±0.2</td>
<td>27° 49’</td>
</tr>
<tr>
<td>F22</td>
<td>98.59±0.64</td>
<td>310.48±2.4</td>
<td>98.97±0.36</td>
<td>0.389±0.03</td>
<td>0.545±0.05</td>
<td>2.56±0.37</td>
<td>28.63±0.3</td>
<td>1.40±0.4</td>
<td>24° 36’</td>
</tr>
</tbody>
</table>

* (n=3); (average±SD)

Fig. 7: Drug-release profile of formulation with varying surfactant concentration and RPM with polymer eudragit L 100 (n=3)

Fig. 8: Drug-release profile of formulation with varying surfactant concentration and RPM with polymer eudragit L 100 (n=3)
Table 6: Data for stability study indicating percentage drug content

<table>
<thead>
<tr>
<th>Formulation code</th>
<th>Percentage drug content</th>
<th>0 Time</th>
<th>2nd mo</th>
<th>4th mo</th>
<th>6th mo</th>
</tr>
</thead>
<tbody>
<tr>
<td>F13</td>
<td>100.51±0.75</td>
<td>100.20±0.54</td>
<td>99.94±0.35</td>
<td>99.58±0.49</td>
<td></td>
</tr>
<tr>
<td>F20</td>
<td>93.42±0.95</td>
<td>93.25±1.20</td>
<td>93.02±0.68</td>
<td>92.68±0.35</td>
<td></td>
</tr>
<tr>
<td>similarity factor (ƒ₂)</td>
<td></td>
<td>67.89</td>
<td>64.25</td>
<td>60.32</td>
<td></td>
</tr>
</tbody>
</table>

(n=6) (average±SD)

CONCLUSION

Sustained release mesalazine microspheres for colon targeting were prepared by a non-aqueous solvent evaporation method using pH sensitive polymers such as eudragit S 100 and eudragit L 100. The microspheres prepared with polymers eudragit S100 and eudragit L 100 were found suitable for colonic release of mesalazine resisting drug release in gastric medium, minimising release in the upper intestinal region and showing maximum release in the colonic region. The effect of variable parameters like concentration of span 80 and RPM was tested on the best formulation and further characterised. Thus the developed formulations prove to be promising for the colon targeted drug delivery of mesalazine and thereby facilitating in the management of ulcerative colitis and inflammatory bowel disease.

ACKNOWLEDGEMENT

The authors are thankful to The Dean, Faculty of Pharmacy, MSRUAS for providing necessary facilities to carry out the research work. The authors thank Indian Institute of Science (IISc), Bangalore for carrying out DSC, XRD and SEM studies.

CONFLICT OF INTERESTS

Declared none

REFERENCES


How to cite this article